Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

The engagement will explore the use of cellular fermentation to make key starting materials required for pharmaceutical ...

Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...

SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...

CRISPR-Cas9 is one of the most commonly leveraged non-viral editing tools to engineer cells for therapeutics applications. It is a nuclease-based genome editing system which has seen exponential ...

TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation (President: Kenji Sukeno) is to invest a total of 3.2 billion yen on its CDMO *1 sites in the U.S.A. and the U.K. in order to accelerate the expansion of ...

BOSTON & SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, ...

Vaccizone has selected Exothera S.A. to fast-track process development of its SARS CoV 2 vaccine for European clinical trials. Vaccizone has developed and patented a novel method for delivering ...

GAINESVILLE, Fla., May 28, 2020 /PRNewswire/ -- Arranta Bio ("Arranta"), the leading microbiome contract development and manufacturing organization (CDMO), today announced completion of its process ...